D&D Pharmatech don announce say dia MASH treatment, Jabofegdutide wey dem dey call DD01, don show strong result for phase 2 clinical trial for United States. Di drug, wey dey target metabolic dysbiosis-related fatty liver disease, don improve liver fibrosis and resolve MASH for patients wey participate for di trial.
Di company release di result of 48-week biopsy on di 27th, and dem present am for European Association for the Study of Liver (EASL 2026) wey happen for Barcelona, Spain. Di clinical trial bin take place for 12 institutions for United States, and dem focus on MASLD and MASH patients wey get overweight and obesity.
According to di result, 50% of di patients wey take DD01 achieve improved liver fibrosis without MASH exacerbation. For MASH treatment development, di key competitiveness na whether di drug fit improve liver tissue, not just make person lose weight. Di industry believe say dis result show possibility of DD01 to differentiate from oda drugs.
One tins wey dey important na say di reduction of liver fat and improvement of liver stiffness bin dey based on GLP-1/glucagon dual action mechanism. For safety side, most gastrointestinal adverse reactions bin mild or moderate. Di company explain say di discontinuation rate similar to competing drugs even during short dose increase period.
Di global pharmaceutical industry dey compete to secure MASH treatments. GlaxoSmithKline (GSK), Roche, and Novo Nordisk dey compete for market with billions of dollars for acquisition. D&D Pharmatech say dem dey for process of technology transfer and strategic partnering discussions with global investment bank (IB).
Di company tok say, “Based on di results, we expect discussions with global pharmaceutical companies to speed up further.” Di market react immediately dat day. D&D Pharmatech stock price rise 30% from previous day to 98,800 won.
